Novo Nordisk initiates phase I trial of oral device
A new Novo Nordisk device, which is designed to be swallowed, will soon be tested in a phase I study according to the Clinical Trials database, but the pharmaceutical firm in charge does not want to divulge further details due to a scheduled quiet period.
by christopher due karlsson, translated by daniel pedersen
Novo Nordisk is taking another step on its road toward developing new technologies for oral drug delivery.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo expands research collaboration with US universities
For subscribers
Novo Nordisk target price increased by five institutions
For subscribers
